|
MechanismMonoamine reuptake inhibitor |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects with Brain Metastases from Non-Small Cell Lung Cancer
Long-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793
A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450 with Ritonavir (ABT- 450/r), ABT-267, and ABT-333 With and Without Ribavirin in Treatment- Experienced Subjects with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PEARL-II).
100 Clinical Results associated with Abbott GmbH (Germany)
0 Patents (Medical) associated with Abbott GmbH (Germany)
100 Deals associated with Abbott GmbH (Germany)
100 Translational Medicine associated with Abbott GmbH (Germany)